Strengthening the team
PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical trial manager to continue the development of the company's drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain.
Inge Tarnow joins the team as the new Senior project manager and will lead and coordinate the work with PN6047. Inge Tarnow holds a Ph.D. in pathophysiology and is a Doctor of Veterinary Medicine. She has worked as a project manager at Savara, a biopharmaceutical company focusing on rare respiratory diseases, for six years.
PharmNovo also welcomes Thomas Eskildsen, Senior Clinical Trial Manager. He will oversee the phase I study while being an asset to the team in the planning and managing future phase IIa studies.
Strengthening the team
PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical trial manager to continue the development of the company's drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain.
Inge Tarnow joins the team as the new Senior project manager and will lead and coordinate the work with PN6047. Inge Tarnow holds a Ph.D. in pathophysiology and is a Doctor of Veterinary Medicine. She has worked as a project manager at Savara, a biopharmaceutical company focusing on rare respiratory diseases, for six years.
PharmNovo also welcomes Thomas Eskildsen, Senior Clinical Trial Manager. He will oversee the phase I study while being an asset to the team in the planning and managing future phase IIa studies.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
